Weight

CagriSema (cagrilintide)

Peptilex evidence grade ABCDEUpdated 19 Oct 2026 How grades work

Type: Analogues of the pancreatic hormone amylin
Main use or focus: Weight management (investigational)
Also known as: CagriSema

Key results

CagriSema: average weight loss% of body weight lost on average

CagriSemaPlaceboSemaglutide

REDEFINE 168 wk · 3,417 participants

20.4%

3.0%

REDEFINE 52026

18.4%

11.9% · Semaglutide

REDEFINE 268 wk · 1,206 participants · with type 2 diabetes

13.7%

3.4%

Different trials, durations and populations – not a head-to-head comparison.

Sources: REDEFINE 1 · NEJM 2025 · REDEFINE 5 · 2026 · REDEFINE 2 · NEJM 2025

Trial	CagriSema	Comparison
REDEFINE 1	20.4%	3.0%
REDEFINE 5	18.4%	11.9% · Semaglutide
REDEFINE 2	13.7%	3.4%

Where it stands

The amylin-plus-semaglutide combination led to 20.4% average weight loss over 68 weeks in REDEFINE 1, and in the 2026 head-to-head trial REDEFINE 5 it reached 18.4% versus 11.9% on semaglutide alone. It was submitted to the FDA in December 2025; a decision is expected in late 2026.

How it works

How the new weight-loss medicines workWhich hormone receptors each one activates

	GLP-1	GIP	Glucagon	Amylin
Liraglutide1×
Semaglutide1×
Tirzepatide2×
Retatrutide3×
CagriSema2×

Source: Peptilex 1, profile overview (type of each peptide)

Go deeper

Full profile in the book

What it is, how it acts, the key studies, risks and open questions.

Peptilex – The Peptide Encyclopedia

34 peptides – from semaglutide to BPC-157 – in one book
An evidence grade (A–E) and the key studies for every peptide
Where each one stands in 2026 – US, EU and Switzerland

View on Amazon

Formats: Kindle · Paperback · Hardcover

Amazon store: amazon.com · Change store

Coming soonPeptilex – The Honest GLP-1 HandbookSemaglutide, tirzepatide and the new pills, explained for adults over 50.

Research at a glance

Publications by typePubMed, all years

All papers121

Human studies76

Animal studies only5

Randomized trials15

Meta-analyses & systematic reviews11

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Registered trials by phaseClinicalTrials.gov · name in study title

ongoing / startingcompleted / other

Phase 115

Phase 24

Phase 321

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Trial starts per yearClinicalTrials.gov · by start date (planned starts included)

12022

122024

102026

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Registered trials

ClinicalTrials.gov · name in study title · ongoing first

Study	Phase	Status	Participants	Start
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels NCT05669755Novo Nordisk A/S	Phase 3	Running	7,101	Mar 2023
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight NCT05567796Novo Nordisk A/S	Phase 3	Running	3,400	Nov 2022
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term NCT07011667Novo Nordisk A/S	Phase 3	Running	609	Jun 2025
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight NCT07253285Novo Nordisk A/S	Phase 3	Recruiting	460	Jan 2026
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity NCT06780449Novo Nordisk A/S	Phase 3	Running	400	Feb 2025
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide NCT07220759Novo Nordisk A/S	Phase 3	Running	330	Nov 2025
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide NCT07220642Novo Nordisk A/S	Phase 3	Running	300	Nov 2025
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight NCT07745504Novo Nordisk A/S	Phase 3	Recruiting	285	Aug 2026
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema NCT07817251Novo Nordisk A/S	Phase 3	Recruiting	210	Sep 2026
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes NCT07282613Novo Nordisk A/S	Phase 3	Recruiting	80	Aug 2026

Show 15 moreShow fewer

Study	Phase	Status	Participants	Start
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism NCT07010432Novo Nordisk A/S	Phase 1	Recruiting	144	Jun 2025
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity NCT07557953Novo Nordisk A/S	Phase 1	Recruiting	120	Apr 2026
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events NCT07607587Novo Nordisk A/S	Phase 1	Recruiting	114	May 2026
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) NCT07527195Novo Nordisk A/S	Phase 1	Recruiting	100	Apr 2026
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet NCT07184086Novo Nordisk A/S	Phase 1	Running	80	Sep 2025
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor NCT06065540Novo Nordisk A/S	Phase 3	Completed	2,734	Sep 2023
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight NCT05394519Novo Nordisk A/S	Phase 3	Completed	1,200	Feb 2023
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor NCT06221969Novo Nordisk A/S	Phase 3	Completed	1,024	Jan 2024
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both NCT06534411Novo Nordisk A/S	Phase 3	Completed	1,023	Nov 2024
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight NCT06131437Novo Nordisk A/S	Phase 3	Completed	809	Nov 2023
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight NCT05813925Novo Nordisk A/S	Phase 3	Completed	331	Apr 2023
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight NCT05996848Novo Nordisk A/S	Phase 3	Completed	300	Aug 2023
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin NCT06323161Novo Nordisk A/S	Phase 3	Completed	274	Mar 2024
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise NCT06323174Novo Nordisk A/S	Phase 3	Completed	189	Mar 2024
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo NCT06131372Novo Nordisk A/S	Phase 2	Completed	626	Apr 2024

Showing 25 of 40 matching registered studies. See all on ClinicalTrials.gov.

Latest key papers

PubMed · newest first

2026
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1
Human RCTBusetto L et al. · Diabetes, Obesity & MetabolismPMID 42503495
2026
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis
Meta-analysisNong K et al. · BMJPMID 42419792
2026
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians
Meta-analysisDamen JAA et al. · Annals of Internal MedicinePMID 42296503
2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
Human RCTPhase 3Aroda VR et al. · Lancet Diabetes & EndocrinologyPMID 42251860
2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Human RCTPhase 3Buse JB et al. · Lancet Diabetes & EndocrinologyPMID 42251859
2026
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Human RCTPhase 3Rosenstock J et al. · The LancetPMID 42251856
2026
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide
Human RCTPhase 1Nielsen MJF et al. · Clinical PharmacokineticsPMID 42228334
2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Meta-analysisHamarsheh S et al. · Endocrinology, Diabetes & MetabolismPMID 42207966

Related peptides

ASemaglutide ATirzepatide BRetatrutide ALiraglutide APramlintide ASetmelanotide CAOD-9604